<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07843R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005073</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cardiovascular Disorders/Coronary Artery Disease</subject><subject>Cardiovascular Disorders/Hypertension</subject><subject>Cardiovascular Disorders/Vascular Biology</subject></subj-group></article-categories><title-group><article-title>Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding</article-title><alt-title alt-title-type="running-head">IL-1 Modulates Blood Pressure</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chamberlain</surname><given-names>Janet</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Francis</surname><given-names>Sheila</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brookes</surname><given-names>Zoe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Delyth</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alp</surname><given-names>Nicholas J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dower</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Crossman</surname><given-names>David C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Cardiovascular Research Unit, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom</addr-line></aff><aff id="aff2"><label>2</label><addr-line>BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Functional Genomics, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Xu</surname><given-names>Aimin</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Department of Medicine, University of Hong Kong, China</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>j.chamberlain@sheffield.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JC SEF ZB DG NA SD DC. Performed the experiments: JC SEF ZB GS DG NA SD DC. Analyzed the data: JC SEF ZB GS DG NA SD DC. Wrote the paper: JC SEF ZB DG NA SD DC.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>6</day><month>4</month><year>2009</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e5073</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2009</year></date></history><copyright-statement>Chamberlain et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Atherosclerosis is an inflammatory process that develops in individuals with known risk factors that include hypertension and hyperlipidaemia, influenced by diet. However, the interplay between diet, inflammatory mechanisms and vascular risk factors requires further research. We hypothesised that interleukin-1 (IL-1) signaling in the vessel wall would raise arterial blood pressure and promote atheroma.</p></sec><sec><title>Methodology/Principal Findings</title><p><italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> mice were fed high fat diets for 8 weeks, and their blood pressure and atherosclerosis development measured. <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice had a reduced blood pressure and significantly less atheroma than <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice. Selective loss of IL-1 signaling in the vessel wall by bone marrow transplantation also reduced plaque burden (p&#x0003c;0.05). This was associated with an IL-1 mediated loss of endothelium-dependent relaxation and an increase in vessel wall Nox 4. Inhibition of IL-1 restored endothelium-dependent vasodilatation and reduced levels of arterial oxidative stress.</p></sec><sec><title>Conclusions/Significance</title><p>The IL-1 cytokine system links atherogenic environmental stimuli with arterial inflammation, oxidative stress, increased blood pressure and atherosclerosis. This is the first demonstration that inhibition of a single cytokine can block the rise in blood pressure in response to an environmental stimulus. IL-1 inhibition may have profound beneficial effects on atherogenesis in man.</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Drugs to decrease plasma lipid levels and blood pressure are the basis of the medical treatment strategy for cardiovascular disease. Dietary modification of macronutrient and salt intakes has also been studied with some large effects upon systolic blood pressure in particular <xref ref-type="bibr" rid="pone.0005073-Appel1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005073-Dickinson1">&#x0005b;3&#x0005d;</xref>. However, the exact interplay between the well-described plaque-based inflammatory processes of atherogenesis <xref ref-type="bibr" rid="pone.0005073-Hansson1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Glass1">&#x0005b;4&#x0005d;</xref> and the conventional risk factors of lipids and blood pressure remains poorly understood. We hypothesized that the pro-inflammatory cytokine interleukin-1 (IL-1), known to have an association with atherosclerosis, is the link between vascular responses and high fat feeding.</p><p>In the arterial wall, IL-1 is secreted primarily by monocytes and macrophages but also by endothelial and smooth muscle cells <xref ref-type="bibr" rid="pone.0005073-Bevilacqua1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Libby1">&#x0005b;6&#x0005d;</xref>. IL-1 is an apical cytokine initiating inflammatory signals from bacterial products, chemical injury, complement activation and clotting factors. There are two agonistic cytokines, IL-1&#x003b1; and &#x003b2; which both signal via the type-I IL-1 receptor (IL-1R1). The system is tightly regulated by a natural antagonist, interleukin-1 receptor antagonist (IL-1ra) which also binds to IL-1R1 but does not produce a signal, and a non-signaling cell surface receptor, IL-1 receptor type-II, which acts as a decoy at the cell membrane or when shed as a soluble circulating decoy receptor <xref ref-type="bibr" rid="pone.0005073-Colotta1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Symons1">&#x0005b;8&#x0005d;</xref>.</p><p>IL-1 is a powerful inflammatory stimulus to endothelial and vascular smooth muscle cells with effects that are plausibly linked with known mechanisms of atherogenesis <xref ref-type="bibr" rid="pone.0005073-Tamaru1">&#x0005b;9&#x0005d;</xref>. Levels of IL-1 are increased in coronary arteries affected by atherosclerosis <xref ref-type="bibr" rid="pone.0005073-Galea1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Dewberry1">&#x0005b;11&#x0005d;</xref>, and inhibition of IL-1 in animal models is associated with reduced amounts of atheroma <xref ref-type="bibr" rid="pone.0005073-Kirii1">&#x0005b;12&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005073-Chi1">&#x0005b;16&#x0005d;</xref> as well as neointima following angioplasty <xref ref-type="bibr" rid="pone.0005073-Morton1">&#x0005b;17&#x0005d;</xref>. Excess IL-1 leads to vascular cell oxidative stress, which is linked with elevation of arterial blood pressure mediated by adverse effects of oxidative stress upon bioavailable nitric oxide.</p><p>We report here the cardiovascular effects of abolishing IL-1 signaling either by genetic deletion of IL-1R1 or by administration of IL-1ra in proatherogenic <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed atherogenic diets. We also show a link between fat feeding and blood pressure that is mediated via IL-1 through modulation of the NADPH-oxidase subunit 4 (Nox 4).</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><p>More detailed methods can be found in the online supplemental material (<xref ref-type="supplementary-material" rid="pone.0005073.s001">Text S1</xref>).</p><sec id="s2a"><title>Animals</title><p><italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice were generated at JAX labs by cross breeding of <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> (JAX 2052) with <italic>IL-R1<sup>&#x02212;/&#x02212;</sup></italic> (JAX 3245) mice. All mice were on a C57BL/6 background. Male mice, 8 weeks of age, (12 per group) were fed normal chow (4.3&#x00025; fat, 0.02&#x00025; cholesterol), Western diet (21&#x00025; fat, 0.15&#x00025; cholesterol, 0.03&#x00025; cholate, 0.296&#x00025; sodium) or Western High Cholate (WHC or Paigen) diet (18.5&#x00025; fat, 0.9&#x00025; cholesterol, 0.5&#x00025; cholate, 0.259&#x00025; sodium) for 8 weeks. No differences in body weights between the strains were observed either with or without fat feeding. Diets were supplied by Special Diet Services, UK. All animal experiments were approved by the University of Sheffield Project Review Committee and conformed to UK Home Office ethical guidelines.</p></sec><sec id="s2b"><title>Quantification of Atherosclerotic Lesions</title><p>Histologically stained paraffin wax embedded sections were analysed as previously described <xref ref-type="bibr" rid="pone.0005073-Chamberlain1">&#x0005b;18&#x0005d;</xref>.</p></sec><sec id="s2c"><title>Blood Pressure Analysis</title><p>Systolic and diastolic blood pressures of mice were measured using a Visitech tail-cuff system (Visitech Systems, NJ, USA) and mean blood pressure calculated (supplementary <xref ref-type="supplementary-material" rid="pone.0005073.s001">text S1</xref>).</p></sec><sec id="s2d"><title>Arteriolar Myogenic Reactivity and Responsiveness to Nitric Oxide</title><p>A pressure myograph system (Living Systems Instrumentation, USA) was used to determine arteriolar myogenic reactivity and responsiveness to nitric oxide, as previously described <xref ref-type="bibr" rid="pone.0005073-Brookes1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Andrew1">&#x0005b;20&#x0005d;</xref>.</p></sec><sec id="s2e"><title>Bone Marrow transplantation</title><p>Irradiation and bone marrow transplantation of mice was performed as previously described <xref ref-type="bibr" rid="pone.0005073-Chamberlain1">&#x0005b;18&#x0005d;</xref> (<xref ref-type="supplementary-material" rid="pone.0005073.s001">text S1</xref>).</p></sec><sec id="s2f"><title>Detection of Reactive Oxygen Species (ROS), NOS and Nitric Oxide</title><p>Superoxide production in mouse aortic tissue sections was detected <italic>in-situ</italic><xref ref-type="bibr" rid="pone.0005073-Alp1">&#x0005b;21&#x0005d;</xref>. Levels of ROS in aortic tissue were determined by chemiluminescent assay <xref ref-type="bibr" rid="pone.0005073-Laursen1">&#x0005b;22&#x0005d;</xref>. Nitric oxide synthase (NOS) enzymatic activity, and indirectly nitric oxide (NO) synthesis, was measured by the conversion of 14C L-arginine to 14C L-citrulline <xref ref-type="bibr" rid="pone.0005073-Alp2">&#x0005b;23&#x0005d;</xref>. These methods are given in detail in the supplementary data. NO bioactivity in mice fed WHC was determined using an enzyme immunoassay for cyclic guanosine monophosphate (cGMP) (Cayman Chemical, UK).</p></sec><sec id="s2g"><title>Quantitative Real time polymerase chain reaction</title><p>Quantification of Nox 2 and Nox 4 was performed by amplification of artery cDNA using a MX3000P instrument (Stratagene) with SYBR green dye, and normalization to 18S rRNA. For cultured cells, normalization was to &#x003b2;-actin. Optimized amplification conditions were 150 mmol/L primers, 2.5 mmol/L MgCl<sub>2</sub>, annealing at 60&#x000b0;C and extension at 72&#x000b0;C. Primer sequences were as described in <xref ref-type="bibr" rid="pone.0005073-Guzik1">&#x0005b;24&#x0005d;</xref>.</p></sec><sec id="s2h"><title>Statistical Analysis</title><p>Data groups were analyzed by t-test or one-way ANOVA followed by a Bonferroni multiple comparison post-test, as appropriate. Blood pressure measurements were analyzed by global non-linear regression, followed by an F-test. Vessel diameters were analyzed by two-way repeated-measures ANOVA. pD<sub>2</sub>, E<sub>max</sub>, L-NAME effects and wall: lumen ratios were compared by t-tests. Data are presented as mean&#x000b1;SEM. p&#x0003c;0.05 was regarded as a significant difference.</p></sec></sec><sec id="s3"><title>Results</title><p>Further results can be found in the online supplementary text (<xref ref-type="supplementary-material" rid="pone.0005073.s002">Results S1</xref>).</p><sec id="s3a"><title>Effects of genetic deletion of IL-1R1 and diet type on atherosclerosis lesion development</title><p>As expected, <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed high fat diets displayed significant increases in atherosclerotic lesion area compared to mice fed chow, with the Western diet with high cholate (WHC) causing the a greatest increase (<xref ref-type="fig" rid="pone-0005073-g001">Figure 1a</xref>). In contrast, lesions developed by <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed these high fat diets were not significantly different to <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed on chow. Analysis of each different diet type separately revealed no significant difference in lesion area of <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed chow (p&#x0200a;&#x0003d;&#x0200a;0.3), or Western diet (p&#x0200a;&#x0003d;&#x0200a;0.4). However, when fed the WHC diet, <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice developed a 36&#x00025; smaller atherosclerotic lesion in the aortic sinus compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice (p&#x0003c;0.001) (<xref ref-type="fig" rid="pone-0005073-g001">Figure 1a</xref>). Representative images of the microscopic appearance of the lesions are shown in <xref ref-type="supplementary-material" rid="pone.0005073.s003">Figure S1</xref>. Characterisation of the lesions revealed no overt differences with respect to strain or diet (<xref ref-type="supplementary-material" rid="pone.0005073.s002">Results S1</xref>, <xref ref-type="supplementary-material" rid="pone.0005073.s010">table S1</xref>, <xref ref-type="supplementary-material" rid="pone.0005073.s011">Table S2</xref>, <xref ref-type="supplementary-material" rid="pone.0005073.s004">figure S2</xref>). Body weight did not differ between mice of any group (data not shown).</p><fig id="pone-0005073-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005073.g001</object-id><label>Figure 1</label><caption><title>Atherosclerosis formation in mice following feeding of a high fat diet.</title><p>Atherosclerotic lesion area in the aortic sinus of <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice (a) and chimeric mice (b) fed a high fat and chow diets. Apoe&#x02192;DN denotes <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/</italic>IL-1R1<sup>&#x02212;/&#x02212;</sup> (DN) mice receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> bone marrow (n&#x0200a;&#x0003d;&#x0200a;3); DN&#x02192;Apoe denotes <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/</italic>IL-1R1<sup>&#x02212;/&#x02212;</sup> marrow (n&#x0200a;&#x0003d;&#x0200a;9).</p></caption><graphic xlink:href="pone.0005073.g001"/></fig></sec><sec id="s3b"><title>Atherosclerotic lesion formation in IL-1R1 chimeric mice fed a WHC diet</title><p><italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> chimeric mice were used to determine the relative contribution of IL-1 signaling in cells derived from the bone marrow and non-bone marrow (tissue cells) upon the development of atherosclerosis following fat feeding. Irradiated <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> bone marrow had large, and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> marrow relatively little, atherosclerosis in their aortic sinus following 8 weeks on a WHC diet, as expected and analogous to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> non-chimeric animals.</p><p>Interestingly, <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> animals receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> bone marrow (i.e. chimera is capable of IL-1 signaling in vessel wall/tissue cells) did not develop a lesion that was significantly different from <italic>Apoe<sup>&#x02212;/</sup></italic> mice receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> marrow (<xref ref-type="fig" rid="pone-0005073-g001">Figure 1b</xref>). In contrast, <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice receiving <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> bone marrow (i.e. chimera is not able to signal via IL-1 in vessel wall/tissue cells) developed a 1.9-fold smaller lesion than the <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> controls (p&#x0003c;0.05). The lesion size between <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> into <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> into <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice also differed significantly (p&#x0003c;0.05) (<xref ref-type="fig" rid="pone-0005073-g001">Figure 1b</xref>).</p><p>Pathological analysis, by chromosome painting, of these animals showed all had engrafted donor marrow (<xref ref-type="supplementary-material" rid="pone.0005073.s005">figure S3</xref>).</p></sec><sec id="s3c"><title>Blood pressure responses to fat feeding</title><p>There was no difference in mean blood pressure in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed the Western, WHC or chow diet (<xref ref-type="fig" rid="pone-0005073-g002">figure 2a</xref>). However, <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed high fat diets had increased blood pressure compared with chow fed animals, with WHC-fed mice having a greater elevation than Western fed animals (p&#x0003c;0.05 WHC vs Western or chow)(<xref ref-type="fig" rid="pone-0005073-g002">figure 2b</xref>).</p><fig id="pone-0005073-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005073.g002</object-id><label>Figure 2</label><caption><title>Blood pressure of mice following feeding of a high fat diet.</title><p>Mean blood pressure in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> (a) and <italic>Apoe<sup>&#x02212;/</sup></italic> (b) mice fed all 3 diets, and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed chow (c) Western (d) and WHC (e). (f) Mean blood pressure in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice administered with hrIL-1ra or placebo, fed WHC diet. n&#x0200a;&#x0003d;&#x0200a;4 for all groups.</p></caption><graphic xlink:href="pone.0005073.g002"/></fig><p>When comparing mouse strains, no difference was seen in mean blood pressure between <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> or <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> fed a normal chow diet over an 8-week period (p&#x0200a;&#x0003d;&#x0200a;ns)(<xref ref-type="fig" rid="pone-0005073-g002">figure 2c</xref>). However, on feeding high fat diets, <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed either the Western or WHC diet had a significantly lower blood pressure (a level comparable to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice on chow diet) than the <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed the equivalent diet (p&#x0003c;0.001; p&#x0003c;0.0001 respectively, <xref ref-type="fig" rid="pone-0005073-g002">figure 2d, 2e</xref>).</p><p><italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice on WHC diets infused with IL-1ra using an osmotic pump also had a significantly lower blood pressure than <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice given placebo (<xref ref-type="fig" rid="pone-0005073-g002">Figure 2f</xref>). Elevations of IL-1ra in these animals was confirmed by ELISA, and found to be 1435.1&#x0002b;/&#x02212;118.7 pg/ml compared to 0.215&#x0002b;/&#x02212;0.1452 pg/ml in placebo mice.</p></sec><sec id="s3d"><title>Effect of IL-1R1 deletion on vascular reactivity and compliance in mice fed WHC diet</title><p>Mesenteric arteries from <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed Western and WHC diets did not differ in their sensitivity to phenylephrine (PE) (<xref ref-type="supplementary-material" rid="pone.0005073.s012">table S3</xref>). However, preconstricted arteries from <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed these diets displayed significantly greater vasodilator sensitivity to acetyl choline (ACh) (p&#x0003c;0.05; <xref ref-type="fig" rid="pone-0005073-g003">Figures 3a and b</xref>) compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> animals. The vasodilatory response to ACh was also significantly different between chow, Western and WHC diets in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice (p&#x0003c;0.05). In <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC diet there was greater constriction (19.1&#x0002b;/&#x02212;1.3&#x00025;) compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> (8.6&#x0002b;/&#x02212;2.7&#x00025;) following incubation with N(G)-nitro-L-arginine methyl ester (L-NAME) (p&#x0200a;&#x0003d;&#x0200a;0.003), without a significant difference between pD<sub>2</sub> (negative logarithm of EC<sub>50</sub>: concentration required for half maximum response) (<xref ref-type="supplementary-material" rid="pone.0005073.s012">table S3</xref>).</p><fig id="pone-0005073-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005073.g003</object-id><label>Figure 3</label><caption><title>Vascular reactivity of arterioles from <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice.</title><p>(a&#x02013;b) &#x00025; maximum dilation of pre-constricted mesenteric arterioles (EC<sub>80</sub>PE) to acetylcholine. (c) Endothelium-independent relaxation responses assessed by superfusion of sodium nitroprusside (SNP) were not different between <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice both fed a WHC diet (n&#x0200a;&#x0003d;&#x0200a;6 per group).</p></caption><graphic xlink:href="pone.0005073.g003"/></fig><p>Both <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice demonstrated similar internal luminal diameters of small mesenteric arteries increased in response to increasing intraluminal pressure (active response), with <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed either diet showing a trend towards a reduced myogenic response (<xref ref-type="supplementary-material" rid="pone.0005073.s006">figure S4a, S4b</xref>). However, only <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC diet demonstrated a greater active pressure-diameter response compared to chow fed <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="supplementary-material" rid="pone.0005073.s006">figure S4a</xref>).</p><p>There was no difference in the wall-to-lumen ratio (vascular smooth muscle thickness/external diameter at 80 mmHg; <italic>h</italic>/R) <xref ref-type="bibr" rid="pone.0005073-Brookes1">&#x0005b;19&#x0005d;</xref> between the two groups (0.115&#x0002b;/&#x02212;0.007 <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> vs 0.111&#x0002b;/&#x02212;0.011 <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic>, n&#x0200a;&#x0003d;&#x0200a;6). Endothelium-independent relaxation responses, assessed by superfusion of sodium nitroprusside (SNP), also did not differ (<xref ref-type="fig" rid="pone-0005073-g003">figure 3c</xref>).</p></sec><sec id="s3e"><title>Effect of IL-1R1 deletion on NO activity, ROS, NOS and NOX expression in mice fed WHC diet</title><p>The induction of Nox4 mRNA and generation of ROS in response to IL-1 stimulation was confirmed in arteriolar endothelial cells (<xref ref-type="supplementary-material" rid="pone.0005073.s007">Figure S5</xref>). ROS were not generated in response to IL-1 in endothelial cells isolated from <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="supplementary-material" rid="pone.0005073.s007">figure S5</xref>). In contrast, Nox 4 mRNA was reduced in IL-1 stimulated vascular smooth muscle cells (VSMC) (<xref ref-type="supplementary-material" rid="pone.0005073.s008">figure S6</xref>) as previously shown <xref ref-type="bibr" rid="pone.0005073-Ellmark1">&#x0005b;25&#x0005d;</xref>.</p><p>The vessel wall mechanisms that could contribute to the observed vascular reactivity effects were investigated by examining the expression of NO, ROS, NOS and Nox isoforms in WHC diet-fed animals, as this diet gave the largest difference in blood pressure and atheroma between animals with and without the ability to signal via IL-1R1.</p><p>NO bioactivity was increased in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed a WHC diet compared with WHC fed <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice (n&#x0200a;&#x0003d;&#x0200a;9&#x02013;11, p&#x0003c;0.05) (<xref ref-type="fig" rid="pone-0005073-g004">Figure 4a</xref>). Activity of eNOS in the presence or absence of eNOS co-factors did not differ between <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed a WHC diet compared with <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice (p&#x0200a;&#x0003d;&#x0200a;ns) (<xref ref-type="fig" rid="pone-0005073-g004">Figure 4b</xref>). Qualitative <italic>in situ</italic> detection of ROS showed production in atherosclerotic plaques was reduced in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC diet (<xref ref-type="fig" rid="pone-0005073-g004">Figure 4c</xref>). Quantitative measurement of aortic ROS production showed ROS to be significantly reduced in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice on a WHC diet (n&#x0200a;&#x0003d;&#x0200a;9, p&#x0003c;0.05)(<xref ref-type="fig" rid="pone-0005073-g004">Figure 4d</xref>). ROS production was also suppressed in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice on a WHC diet by a 4-week infusion of IL-1ra (n&#x0200a;&#x0003d;&#x0200a;3, p&#x0003c;0.05)(<xref ref-type="fig" rid="pone-0005073-g004">Figure 4e</xref>). Generation of ROS in response to feeding a high fat diet was also confirmed (<xref ref-type="supplementary-material" rid="pone.0005073.s009">figure S7</xref>). <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC had significantly more ROS than those fed chow alone, with Western diet giving intermediate levels of ROS. ROS levels were also significantly higher in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC compared to chow (0.85&#x0002b;/&#x02212;0.14 compared to 0.51&#x0002b;/&#x02212;0.30 LU/g tissue, n&#x0200a;&#x0003d;&#x0200a;9, p&#x0003c;0/01).</p><fig id="pone-0005073-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005073.g004</object-id><label>Figure 4</label><caption><title>NO activity, ROS and NOS expression in mice fed WHC diet.</title><p>(a) cGMP in lung homogenates (n&#x0200a;&#x0003d;&#x0200a;14), (b) eNOS enzymatic activity (n&#x0200a;&#x0003d;&#x0200a;6) and (c) <italic>in-situ</italic> ROS (white arrowhead) in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC. <italic>(Note: images chosen illustrate ROS levels not atherosclerotic lesion size)</italic>. Chemiluminescent quantification of ROS in mice fed WHC (d) and <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC diet (n&#x0200a;&#x0003d;&#x0200a;9) and administered hrIL-1ra (n&#x0200a;&#x0003d;&#x0200a;4) (e).</p></caption><graphic xlink:href="pone.0005073.g004"/></fig><p>Nox 4 expression in the whole arterial wall was significantly reduced in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed the WHC diet compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="fig" rid="pone-0005073-g005">Figure 5a</xref>). Expression of Nox 1 and 2 however, did not differ between these two mouse strains on this diet (<xref ref-type="fig" rid="pone-0005073-g005">figure 5b, 5c</xref>).</p><fig id="pone-0005073-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005073.g005</object-id><label>Figure 5</label><caption><title>Nox expression following feeding of WHC diet.</title><p>Expression of Nox is selectively reduced in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC. (a) qRT-PCR shows reduced (p&#x0003c;0.05) levels of Nox 4 in the vascular wall of <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC diet. Levels of Nox 2 (b) and Nox 1 (c) do not differ. n&#x0200a;&#x0003d;&#x0200a;12 per group.</p></caption><graphic xlink:href="pone.0005073.g005"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>The <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mouse fed a high fat diet is an established model of atherogenesis. On a Western or a Western high cholate diet (WHC, sometimes called the Paigen diet), <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice develop aortic atheroma <xref ref-type="bibr" rid="pone.0005073-Getz1">&#x0005b;26&#x0005d;</xref> and blood pressure is known to rise within 1 to 3 months of feeding. We show here that IL-1 inhibition reduces atheroma formation and prevents the associated rise in blood pressure in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed high fat diets.</p><p>IL-1 inhibition was achieved by generating mice deficient for both <italic>Apoe</italic> and IL-1 receptor 1 (IL-1R1) genes. As expected, aortic atheroma was significantly reduced in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed WHC compared with <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> controls. This is in agreement with previous studies that showed decreased atherosclerosis in IL-1&#x003b2;<sup>&#x02212;/&#x02212;</sup> and IL-1&#x003b1;<sup>&#x02212;/&#x02212;</sup> mice fed a high cholate diet <xref ref-type="bibr" rid="pone.0005073-Kamari1">&#x0005b;27&#x0005d;</xref> and with data from a heterozygote <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> model <xref ref-type="bibr" rid="pone.0005073-Chi1">&#x0005b;16&#x0005d;</xref>. In addition, both high fat diets were associated with increased markers of inflammation that were attenuated in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="supplementary-material" rid="pone.0005073.s002">Results S1</xref>). Interestingly, IL-1&#x003b2; and IL-1ra plasma levels in mice were not changed in response to fat-feeding, This was not unexpected: mature plasma IL-1&#x003b2; is a difficult parameter to interpret as a non-secreted protein and IL-1ra behaves as an acute phase reactant with a large variation in levels <xref ref-type="bibr" rid="pone.0005073-Ray1">&#x0005b;28&#x0005d;</xref>. Any true changes in inflammatory markers are more likely to occur locally within the vessel wall itself.</p><p><italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice fed a high fat diet display a rise in blood pressure that is not seen in <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice fed equivalent diets. The specificity of this was confirmed by abolition of the fat-feeding induced blood pressure rise in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice given IL-1ra. Stroke-prone spontaneously hypertensive rats (SHRSP) showed no difference in blood pressure if given IL-1ra (data not shown), suggesting that IL-1ra does not act as a non-specific vasodilator.</p><p>To study the mechanism of the attenuation of the blood pressure rise in the <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> mice we investigated active arteriolar pressure-diameter responses and basal and agonist-induced NO production in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup></italic> fat-fed mice. The greater vessel diameter in response to increasing pressure in vessels from <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/ILR1<sup>&#x02212;/&#x02212;</sup></italic>, together with no observed difference in sensitivity to PE between groups or in vascular smooth muscle constriction for the given degree of muscle shortening (wall: lumen ratio), as well as the preserved response to SNP, all suggest a specific endothelial response.</p><p>The strikingly preserved agonist-induced NO dependent vasodilatation of resistance vessels from <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> mice compared to <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> in both diet groups as well as the greater contraction in response to L-NAME in the fat-fed <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> mice indicate a fundamental increase in bioavailable vessel wall nitric oxide as a result of selective loss of IL-1 signaling. This is emphasised by the observed increase in basal cGMP production seen in these mice. The activity of eNOS, in the presence or absence of eNOS co-factors, did not differ between the two mouse strains suggesting that the difference in bioavailable NO attributable to selective IL-1 inhibition is mediated by increased consumption of NO via increased arterial oxidative stress.</p><p>In support of these data, there was consistent reduction of arterial ROS levels in mice unable to signal via IL-1. Investigation of Nox isoforms, known to regulate NADPH activity <xref ref-type="bibr" rid="pone.0005073-Bedard1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Kaur1">&#x0005b;30&#x0005d;</xref>, indicated a Nox-4 selective rise in response to fat feeding in the <italic>Apoe</italic><sup>&#x02212;/&#x02212;</sup> mouse attenuated by abolition of IL-1 signaling. Taken together, these results suggest a central role for IL-1 in modulating the blood pressure response to high lipids and that this is via a selective reduction in bioavailable nitric oxide.</p><p>The chimeric mouse experiments were conducted to examine the compartment in which IL-1 signaling was important. Only in chimeras where tissue cells were unable to signal via IL-1 was a there a decrease in atherosclerotic lesion size. These data complement a recent study by Kamari <italic>et al.</italic> who showed reduced atherosclerosis in wild type, WHC-fed mice reconstituted with either IL-1&#x003b2;<sup>&#x02212;/&#x02212;</sup> or IL-1&#x003b1;<sup>&#x02212;/&#x02212;</sup> bone marrow <xref ref-type="bibr" rid="pone.0005073-Kamari1">&#x0005b;27&#x0005d;</xref>.</p><p>We also demonstrate that vessel wall ROS production and Nox 4 levels are altered between the non-chimeric <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> and <italic>Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup></italic> strains on high fat diets. The myography experiments also suggest a selective endothelial loss of function. Thus, the data presented here add to the hypothesis that IL-1 signaling within the blood vessel wall cells is the mechanism involved in the blood pressure and atherogenic responses to fat feeding in <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice.</p><p>Our studies examined the effects of two different pro-atherogenic diets, administered for 8 weeks. Of these diets, the WHC diet is known to be the most aggressive, giving a chronic inflammatory response compared to the acute response of a standard Western (high cholesterol/low cholate) diet <xref ref-type="bibr" rid="pone.0005073-Vergnes1">&#x0005b;31&#x0005d;</xref>. Besides being a normal component of bile in vertebrates, cholate (E1000) is an emulsifier and foam stabilizing agent used in food manufacturing which leads to very high circulating cholesterol concentrations in plasma. Given the difference in plasma cholesterol load, it is interesting that the poor vascular reactivities of vessels from mice fed both diets were similar with a clear gain of function seen in mice lacking the ability to signal via IL-1R1, irrespective of the cholate content. Atheroma development and blood pressure elevation were graded in magnitude through chow to the Western and WHC diets, with the WHC having the greatest effect. In keeping with this, the greatest level of attenuation of biological events by IL-1 inhibition was seen in the WHC diet fed animals. These all suggest a specificity of IL-1 in the mediation of fat fed vascular events.</p><p>The WHC diet can cause intense metabolic disruption, hepatic dysfunction and inflammatory activation. We did not see these effects. Additionally, we saw similar index data (e.g. blood pressure and atheroma formation) for mice fed on the Western and the WHC diet, though the magnitude of the blood pressure effects was reduced with the Western diet. We feel, therefore, that where we have used the WHC diet for further detailed experimentation that this is justified and that the results derived are the result of elevation in cholesterol: the Western diet giving intermediate cholesterol levels and intermediate phenotype, and the WHC diet giving rise to high cholesterol and an advanced phenotype.</p><p>There is considerable interest in harnessing knowledge of basic inflammatory mechanisms of atherogenesis for therapeutic benefit. We show that dietary manipulation in a murine model of atherosclerosis is associated with a rise in blood pressure, an effect attenuated by selective inhibition of a single cytokine. High fat diets may be particularly linked with elevation in blood pressure <xref ref-type="bibr" rid="pone.0005073-Dickinson1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Wilde1">&#x0005b;32&#x0005d;</xref>. It is clear that in humans, dietary alterations away from a standard Western diet to those lower in fat, but which are isocaloric and balanced for sodium content, or which are supplemented with omega-3 fatty acids, also lower blood pressure <xref ref-type="bibr" rid="pone.0005073-Appel1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005073-Morris1">&#x0005b;33&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005073-Yang1">&#x0005b;35&#x0005d;</xref>. Omega-3 fatty acids have also been shown to reduce cyclooxygenase-2 and NADPH oxidase activity <xref ref-type="bibr" rid="pone.0005073-Massaro1">&#x0005b;36&#x0005d;</xref>, both of which are induced by IL-1. This suggests that the link between diet and blood pressure may be through the IL-1 cytokine system, and may indicate a role for IL-1 inhibition in the control of hypertension in man.</p><p>In our experiments, there was a concomitant reduction in blood pressure and atheroma development. In fat-fed <italic>Apoe<sup>&#x02212;/&#x02212;</sup></italic> mice, development of atheroma is not driven directly by the rise in blood pressure <xref ref-type="bibr" rid="pone.0005073-Chen1">&#x0005b;37&#x0005d;</xref>. It seems likely therefore, that the IL-1 mediated increase in ROS and decreased NO production are the central mechanism of atheroma development as both of these have individually been implicated in atherogenesis. The absence of difference in lipid levels between the different mouse strains on the same diets (<xref ref-type="supplementary-material" rid="pone.0005073.s002">results S1</xref>) confirms the likely effect of IL-1 inhibition on atherogenesis being a ROS/NO-based mechanism.</p><p>These data raise the possibility of an entirely novel strategy for prevention of atherosclerosis. An anti-IL-1 based approach would be expected to have a beneficial effect upon atherogenic mechanisms at multiple levels. Indeed, very recent data have indicated a beneficial effect of IL-1ra upon patients with type II diabetes <xref ref-type="bibr" rid="pone.0005073-Larsen1">&#x0005b;38&#x0005d;</xref>, ventricular function <xref ref-type="bibr" rid="pone.0005073-Ikonomidis1">&#x0005b;39&#x0005d;</xref> and myocardial infarction in mice <xref ref-type="bibr" rid="pone.0005073-Abbate1">&#x0005b;40&#x0005d;</xref> and a similar approach might allow mitigation of the atherogenic potential of Western diets. We anticipate that targeted pharmacological intervention to inhibit IL-1 in man will be beneficial in preventing atheroma development and the clinical consequences that arise from this important disease of developed nations.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005073.s001"><label>Text S1</label><caption><p>Expanded methods.</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0005073.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s002"><label>Results S1</label><caption><p>Additional data</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0005073.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s003"><label>Figure S1</label><caption><p>Microscopic appearances around the aortic sinus of ApoE<sup>&#x02212;/&#x02212;</sup> mice fed chow, Western, and WHC compared with ApoE<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup> mice. Original magnification&#x000d7;2.</p><p>(1.18 MB TIF)</p></caption><media xlink:href="pone.0005073.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s004"><label>Figure S2</label><caption><p>Modulation of IL-1 signaling decreases acute phase reactant serum amyloid A (SAA) levels. SAA was elevated in Apoe<sup>&#x02212;/&#x02212;</sup> mice on both high fat diets, an increase that was significantly reduced in the Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup> mice on equivalent diets. (n&#x0200a;&#x0003d;&#x0200a;9&#x02013;20)</p><p>(4.80 MB TIF)</p></caption><media xlink:href="pone.0005073.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s005"><label>Figure S3</label><caption><p>Chromosome painting of bone-marrow transplanted mice. No Y-chromosomes were seen in male mice transplanted with female bone marrow, confirming engraftment was successful. Male recipients of male bone marrow all have Y-chromosomes, as expected, as a positive control for this method.</p><p>(2.45 MB TIF)</p></caption><media xlink:href="pone.0005073.s005.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s006"><label>Figure S4</label><caption><p>Vascular reactivity of arterioles from Apoe<sup>&#x02212;/&#x02212;</sup> and Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup> mice. Intraluminal arteriolar diameter in response to increasing pressure (0&#x02013;120 mmHg). &#x0002a;P&#x0003c;0.05 Apoe<sup>&#x02212;/&#x02212;</sup>/IL-R1<sup>&#x02212;/&#x02212;</sup> (n&#x0200a;&#x0003d;&#x0200a;6) and &#x0002a;&#x0002a;P&#x0003c;0.05 Apoe<sup>&#x02212;/&#x02212;</sup> WHC (n&#x0200a;&#x0003d;&#x0200a;6) versus Apoe<sup>&#x02212;/&#x02212;</sup> chow (n&#x0200a;&#x0003d;&#x0200a;4).</p><p>(0.61 MB TIF)</p></caption><media xlink:href="pone.0005073.s006.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s007"><label>Figure S5</label><caption><p>ROS and Nox 4 expression in endothelial cells in culture. Increased ROS are seen following IL-1&#x003b2; stimulation of endothelial cells isolated from Apoe<sup>&#x02212;/&#x02212;</sup> mice (n&#x0200a;&#x0003d;&#x0200a;6) (a) and human coronary endothelial cells (hCAEC) (n&#x0200a;&#x0003d;&#x0200a;6) (b). However, no increase in ROS are seen in ECs isolated from Apoe<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup> mice (n&#x0200a;&#x0003d;&#x0200a;6) (a). Nox 4 mRNA expression is increased in hCAEC stimulated with IL-1&#x003b2; (n&#x0200a;&#x0003d;&#x0200a;5) (c).</p><p>(9.90 MB TIF)</p></caption><media xlink:href="pone.0005073.s007.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s008"><label>Figure S6</label><caption><p>ROS and Nox 4 expression in vascular smooth muscle cells in culture. No significant difference in ROS are seen following IL-1&#x003b2; stimulation of VSMCs (n&#x0200a;&#x0003d;&#x0200a;6) (a). Nox 4 mRNA expression is decreased in VSMC stimulated with IL-1&#x003b2; (n&#x0200a;&#x0003d;&#x0200a;1) (b).</p><p>(0.30 MB TIF)</p></caption><media xlink:href="pone.0005073.s008.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s009"><label>Figure S7</label><caption><p>ROS generation in Apoe<sup>&#x02212;/&#x02212;</sup> mice following feeding of a high fat diet. Mice fed WHC had significantly more ROS than those fed chow alone, with Western diet giving intermediate levels of ROS. (n&#x0200a;&#x0003d;&#x0200a;9).</p><p>(2.79 MB TIF)</p></caption><media xlink:href="pone.0005073.s009.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s010"><label>Table S1</label><caption><p>Lipid, glucose and ALT levels in ApoE<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup> and ApoE<sup>&#x02212;/&#x02212;</sup> mice fed chow, Western High Cholate (WHC), and Western diets. Data represents mean&#x0002b;/&#x02212;SEM.</p><p>(0.05 MB DOC)</p></caption><media xlink:href="pone.0005073.s010.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s011"><label>Table S2</label><caption><p>Plasma levels of IL-1ra, IL-1&#x003b2;, IL-1&#x003b1; and IL-6 in ApoE<sup>&#x02212;/&#x02212;</sup>/IL-1R1<sup>&#x02212;/&#x02212;</sup> and ApoE<sup>&#x02212;/&#x02212;</sup> mice fed chow, Western high cholate (WHC), and Western diets, determined by ELISA. Data represents mean&#x0002b;/&#x02212;SEM.</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0005073.s011.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005073.s012"><label>Table S3</label><caption><p>Potency and efficacy of vasoconstrictor response to phenylephrine in pressurised mesenteric arterioles from Apoe<sup>&#x02212;/&#x02212;</sup>/IL1R1<sup>&#x02212;/&#x02212;</sup> and Apoe<sup>&#x02212;/&#x02212;</sup> mice fed a Western high cholate (WHC), Western, or Apoe<sup>&#x02212;/&#x02212;</sup> mice fed chow diet, assessed by pD2 (negative logarithm of EC50: concentration required for half maximum response) and Emax (percentage maximum constriction). All data are means&#x0002b;SEM. p&#x0200a;&#x0003d;&#x0200a;ns.</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0005073.s012.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank Nadine Arnold, Dr Andrea King, Dr Victoria Ridger, Dr Karim Jetha (Univ Sheffield), Dr Kim Suvarna (Department of Histopathology, Northern General Hospital, Sheffield, UK) for their contribution towards this manuscript. Amgen Inc provided the IL-1ra used in this study.</p></ack><ref-list><title>References</title><ref id="pone.0005073-Appel1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><name><surname>Carey</surname><given-names>VJ</given-names></name><name><surname>Obarzanek</surname><given-names>E</given-names></name><name><surname>Swain</surname><given-names>JF</given-names></name><etal/></person-group><year>2005</year><article-title>Effects of protein, monosaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial.</article-title><source>JAMA</source><volume>294</volume><fpage>2455</fpage><lpage>2464</lpage><pub-id pub-id-type="pmid">16287956</pub-id></citation></ref><ref id="pone.0005073-Hansson1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><year>2005</year><article-title>Inflammation, Atherosclerosis and Coronary artery Disease.</article-title><source>N Engl J Med</source><volume>352</volume><fpage>1685</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">15843671</pub-id></citation></ref><ref id="pone.0005073-Dickinson1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>HO</given-names></name><name><surname>Mason</surname><given-names>JM</given-names></name><name><surname>Nicolson</surname><given-names>DJ</given-names></name><name><surname>Campbell</surname><given-names>F</given-names></name><name><surname>Beyer</surname><given-names>FR</given-names></name><etal/></person-group><year>2006</year><article-title>Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials.</article-title><source>J Hypertens</source><volume>24</volume><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">16508562</pub-id></citation></ref><ref id="pone.0005073-Glass1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><year>2001</year><article-title>Atherosclerosis: The Road Ahead.</article-title><source>Cell</source><volume>104</volume><fpage>503</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">11239408</pub-id></citation></ref><ref id="pone.0005073-Bevilacqua1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bevilacqua</surname><given-names>MP</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Majeau</surname><given-names>GR</given-names></name><name><surname>Cotran</surname><given-names>RS</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names></name></person-group><year>1984</year><article-title>Interleukin-1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.</article-title><source>J Exp Med</source><volume>160</volume><fpage>618</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">6332168</pub-id></citation></ref><ref id="pone.0005073-Libby1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Birinyi</surname><given-names>LK</given-names></name><name><surname>Auger</surname><given-names>KR</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><year>1986</year><article-title>Inducible interleukin-1 gene expression in human vascular smooth muscle cells.</article-title><source>J Clin Invest</source><volume>78</volume><fpage>1432</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">3491091</pub-id></citation></ref><ref id="pone.0005073-Colotta1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colotta</surname><given-names>F</given-names></name><name><surname>Dower</surname><given-names>SK</given-names></name><name><surname>Sims</surname><given-names>JE</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><year>1994</year><article-title>The Type II &#x02018;decoy&#x02019; receptor ; a novel regulatory pathway for IL-1.</article-title><source>Immunol Today</source><volume>15</volume><fpage>562</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">7848516</pub-id></citation></ref><ref id="pone.0005073-Symons1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Symons</surname><given-names>JA</given-names></name><name><surname>Young</surname><given-names>PR</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><year>1995</year><article-title>Soluble type II IL-1 receptor binds and blocks processing of IL-1beta precursor and loses affinity for IL-1ra.</article-title><source>Proc Natl Acad Sci USA</source><volume>92</volume><fpage>1714</fpage><lpage>1718</lpage><pub-id pub-id-type="pmid">7878046</pub-id></citation></ref><ref id="pone.0005073-Tamaru1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamaru</surname><given-names>M</given-names></name><name><surname>Tomura</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Tezuka</surname><given-names>K</given-names></name><name><surname>Tamatani</surname><given-names>T</given-names></name><etal/></person-group><year>1998</year><article-title>Interleukin-1 beta induces tissue- and cell-specific expression of adhesion molecules in vivo.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>18</volume><fpage>1292</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">9714137</pub-id></citation></ref><ref id="pone.0005073-Galea1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galea</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Gadsdon</surname><given-names>P</given-names></name><name><surname>Holden</surname><given-names>H</given-names></name><name><surname>Francis</surname><given-names>SE</given-names></name><etal/></person-group><year>1996</year><article-title>IL-1beta in the coronary arteries of patients with ischaemic heart disease.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>16</volume><fpage>1000</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">8696938</pub-id></citation></ref><ref id="pone.0005073-Dewberry1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dewberry</surname><given-names>R</given-names></name><name><surname>Holden</surname><given-names>H</given-names></name><name><surname>Crossman</surname><given-names>D</given-names></name><name><surname>Francis</surname><given-names>S</given-names></name></person-group><year>2000</year><article-title>Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>20</volume><fpage>2394</fpage><lpage>2400</lpage><pub-id pub-id-type="pmid">11073843</pub-id></citation></ref><ref id="pone.0005073-Kirii1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirii</surname><given-names>H</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>Lack of interleukin-1&#x003b2; decreases the severity of atherosclerosis in Apo-E deficient mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>23</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">12615675</pub-id></citation></ref><ref id="pone.0005073-Elhage1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elhage</surname><given-names>R</given-names></name><name><surname>Maret</surname><given-names>A</given-names></name><name><surname>Pieraggi</surname><given-names>MT</given-names></name><name><surname>Thiers</surname><given-names>JC</given-names></name><name><surname>Arnal</surname><given-names>JF</given-names></name><etal/></person-group><year>1998</year><article-title>Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice.</article-title><source>Circulation</source><volume>97</volume><fpage>242</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">9462524</pub-id></citation></ref><ref id="pone.0005073-Isoda1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isoda</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Ishigami</surname><given-names>N</given-names></name><name><surname>Matsuki</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><etal/></person-group><year>2004</year><article-title>Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>24</volume><fpage>1068</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">15059807</pub-id></citation></ref><ref id="pone.0005073-Devlin1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>CM</given-names></name><name><surname>Kuriakose</surname><given-names>G</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><year>2002</year><article-title>Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size.</article-title><source>Proc Natl Acad Sci USA</source><volume>99</volume><fpage>6280</fpage><lpage>6285</lpage><pub-id pub-id-type="pmid">11983917</pub-id></citation></ref><ref id="pone.0005073-Chi1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>H</given-names></name><name><surname>Messas</surname><given-names>E</given-names></name><name><surname>Levine</surname><given-names>RA</given-names></name><name><surname>Graves</surname><given-names>DT</given-names></name><name><surname>Amar</surname><given-names>S</given-names></name></person-group><year>2004</year><article-title>IL-1 Receptor signaling mediates atherosclerosis associated with bacterial exposure and/or high fat diet in a murine apolipoprotein E Heterozygote model.</article-title><source>Circulation</source><volume>110</volume><fpage>1678</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">15353494</pub-id></citation></ref><ref id="pone.0005073-Morton1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>AC</given-names></name><name><surname>Arnold</surname><given-names>ND</given-names></name><name><surname>Gunn</surname><given-names>J</given-names></name><name><surname>Varcoe</surname><given-names>R</given-names></name><name><surname>Francis</surname><given-names>SE</given-names></name><etal/></person-group><year>2005</year><article-title>Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model.</article-title><source>Cardiovasc Res</source><volume>68</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">16099441</pub-id></citation></ref><ref id="pone.0005073-Chamberlain1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>D</given-names></name><name><surname>Dower</surname><given-names>S</given-names></name><name><surname>Crossman</surname><given-names>D</given-names></name><name><surname>Francis</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>IL-1&#x003b2; and signaling of IL-1 in vascular wall and circulating cells modulates the extent of neointima formation after vascular injury in mice.</article-title><source>Am J Pathol</source><volume>168</volume><fpage>1396</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">16565512</pub-id></citation></ref><ref id="pone.0005073-Brookes1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brookes</surname><given-names>ZL</given-names></name><name><surname>Kaufman</surname><given-names>S</given-names></name></person-group><year>2003</year><article-title>Myogenic responses and compliance of mesenteric and splenic vasculature in the rat.</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><volume>284</volume><fpage>R1604</fpage><lpage>R1610</lpage><pub-id pub-id-type="pmid">12609815</pub-id></citation></ref><ref id="pone.0005073-Andrew1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrew</surname><given-names>PS</given-names></name><name><surname>Kaufman</surname><given-names>S</given-names></name></person-group><year>2003</year><article-title>Guanylyl cyclase mediates ANP-induced vasoconstriction of murine splenic vessels.</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><volume>284</volume><fpage>R1567</fpage><lpage>R1571</lpage><pub-id pub-id-type="pmid">12573977</pub-id></citation></ref><ref id="pone.0005073-Alp1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alp</surname><given-names>NJ</given-names></name><name><surname>McAteer</surname><given-names>MA</given-names></name><name><surname>Khoo</surname><given-names>J</given-names></name><name><surname>Choudhury</surname><given-names>RP</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name></person-group><year>2004</year><article-title>Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>24</volume><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">14707037</pub-id></citation></ref><ref id="pone.0005073-Laursen1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laursen</surname><given-names>JB</given-names></name><name><surname>Somers</surname><given-names>M</given-names></name><name><surname>Kurz</surname><given-names>S</given-names></name><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Warnholtz</surname><given-names>A</given-names></name><etal/></person-group><year>2001</year><article-title>Endothelial regulation of vasomotion in ApoE-deficient mice. Implications for interactions between peroxynitrite and tetrahydrobiopterin.</article-title><source>Circulation</source><volume>103</volume><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">11238274</pub-id></citation></ref><ref id="pone.0005073-Alp2"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alp</surname><given-names>NJ</given-names></name><name><surname>Mussa</surname><given-names>S</given-names></name><name><surname>Khoo</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Guzik</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>725</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">12952921</pub-id></citation></ref><ref id="pone.0005073-Guzik1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name><name><surname>Guzik</surname><given-names>B</given-names></name><name><surname>Jopek</surname><given-names>A</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name><etal/></person-group><year>2006</year><article-title>Coronary artery superoxide production and Nox isoform expression in human coronary artery disease.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>26</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">16293794</pub-id></citation></ref><ref id="pone.0005073-Ellmark1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellmark</surname><given-names>SH</given-names></name><name><surname>Dusting</surname><given-names>GJ</given-names></name><name><surname>Fui</surname><given-names>MW</given-names></name><name><surname>Guzzo-Pernell</surname><given-names>N</given-names></name><name><surname>Drummond</surname><given-names>GR</given-names></name></person-group><year>2005</year><article-title>The contribution of Nox 4 to NADPH oxidase activity in mouse vascular smooth muscle.</article-title><source>Cardiovascular Research</source><volume>65</volume><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">15639489</pub-id></citation></ref><ref id="pone.0005073-Getz1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Getz</surname><given-names>GA</given-names></name><name><surname>Reardon</surname><given-names>CA</given-names></name></person-group><year>2006</year><article-title>Diet and murine atherosclerosis.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>26</volume><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">16373607</pub-id></citation></ref><ref id="pone.0005073-Kamari1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamari</surname><given-names>Y</given-names></name><name><surname>Werman-Venkert</surname><given-names>R</given-names></name><name><surname>Shaish</surname><given-names>A</given-names></name><name><surname>Werman</surname><given-names>A</given-names></name><name><surname>Harari</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Differential role and tissue specificity of interleukin-1&#x003b1; gene expression in atherogenesis and lipid metabolism.</article-title><source>Atherosclerosis</source><volume>195</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17173923</pub-id></citation></ref><ref id="pone.0005073-Ray1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Camp</surname><given-names>NJ</given-names></name><name><surname>Benett</surname><given-names>CE</given-names></name><name><surname>Francis</surname><given-names>SE</given-names></name><name><surname>Crossman</surname><given-names>DC</given-names></name></person-group><year>2002</year><article-title>Genetic variation at the IL-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes.</article-title><source>Clinical Science</source><volume>103</volume><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">12193156</pub-id></citation></ref><ref id="pone.0005073-Bedard1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bedard</surname><given-names>K</given-names></name><name><surname>Krause</surname><given-names>K-H</given-names></name></person-group><year>2007</year><article-title>The NOX family of ROS-generating NADPH oxidases: Physiology and Pathophysiology.</article-title><source>Physiol Rev</source><volume>87</volume><fpage>245</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">17237347</pub-id></citation></ref><ref id="pone.0005073-Kaur1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>J</given-names></name><name><surname>Dhaunsi</surname><given-names>GS</given-names></name><name><surname>Turner</surname><given-names>RB</given-names></name></person-group><year>2004</year><article-title>Interleukin-1 and Nitric Oxide increase NADPH oxidase activity in human coronary artery smooth muscle cells.</article-title><source>Medical Principles and Practice</source><volume>13</volume><fpage>26</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">14657615</pub-id></citation></ref><ref id="pone.0005073-Vergnes1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vergnes</surname><given-names>L</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>M</given-names></name><name><surname>Tafuri</surname><given-names>S</given-names></name><name><surname>Reue</surname><given-names>K</given-names></name></person-group><year>2003</year><article-title>Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>42774</fpage><lpage>42784</lpage><pub-id pub-id-type="pmid">12923166</pub-id></citation></ref><ref id="pone.0005073-Wilde1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilde</surname><given-names>DW</given-names></name><name><surname>Massey</surname><given-names>KD</given-names></name><name><surname>Walker</surname><given-names>GK</given-names></name><name><surname>Vollmer</surname><given-names>A</given-names></name><name><surname>Grekin</surname><given-names>RJ</given-names></name></person-group><year>2000</year><article-title>High-fat diet elevates blood pressure and cerebrovascular muscle Ca(2&#x0002b;) current.</article-title><source>Hypertension</source><volume>35</volume><fpage>832</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">10720603</pub-id></citation></ref><ref id="pone.0005073-Morris1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MC</given-names></name><name><surname>Sacks</surname><given-names>F</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name></person-group><year>1993</year><article-title>Does fish oil lower blood pressure? A meta-analysis of controlled trials.</article-title><source>Circulation</source><volume>88</volume><fpage>523</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">8339414</pub-id></citation></ref><ref id="pone.0005073-Takeuchi1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>C</given-names></name><name><surname>Noda</surname><given-names>R</given-names></name><name><surname>Sekine</surname><given-names>S</given-names></name><name><surname>Murano</surname><given-names>Y</given-names></name><etal/></person-group><year>2007</year><article-title>Antihypertensive effect and safety of dietary alpha-linolenic acid in subjects with high-normal blood pressure and mild hypertension.</article-title><source>J Oleo Sci</source><volume>56</volume><fpage>347</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">17898501</pub-id></citation></ref><ref id="pone.0005073-Yang1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Kenny</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>The role of fish oil in hypertension.</article-title><source>Conn Med</source><volume>71</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">17966723</pub-id></citation></ref><ref id="pone.0005073-Massaro1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massaro</surname><given-names>M</given-names></name><name><surname>Habib</surname><given-names>A</given-names></name><name><surname>Lubrano</surname><given-names>L</given-names></name><name><surname>Del Turco</surname><given-names>S</given-names></name><name><surname>Lazzerini</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition.</article-title><source>Proc Natl Acad Sci USA</source><volume>103</volume><fpage>15184</fpage><lpage>15189</lpage><pub-id pub-id-type="pmid">17018645</pub-id></citation></ref><ref id="pone.0005073-Chen1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kuhlencordt</surname><given-names>PJ</given-names></name><name><surname>Astern</surname><given-names>J</given-names></name><name><surname>Gyurko</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>PL</given-names></name></person-group><year>2001</year><article-title>Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice.</article-title><source>Circulation</source><volume>104</volume><fpage>2391</fpage><lpage>2394</lpage><pub-id pub-id-type="pmid">11705813</pub-id></citation></ref><ref id="pone.0005073-Larsen1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>CM</given-names></name><name><surname>Faulenbach</surname><given-names>M</given-names></name><name><surname>Vaag</surname><given-names>A</given-names></name><name><surname>V&#x000f8;lund</surname><given-names>A</given-names></name><name><surname>Ehses</surname><given-names>JA</given-names></name><etal/></person-group><year>2007</year><article-title>Interleukin-1-receptor antagonist in type 2 diabetes mellitus.</article-title><source>N Engl J Med</source><volume>356</volume><fpage>1517</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">17429083</pub-id></citation></ref><ref id="pone.0005073-Ikonomidis1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidis</surname><given-names>I</given-names></name><name><surname>Lekakis</surname><given-names>JP</given-names></name><name><surname>Nikolaou</surname><given-names>M</given-names></name><name><surname>Paraslevaidis</surname><given-names>I</given-names></name><name><surname>Andreadou</surname><given-names>I</given-names></name><etal/></person-group><year>2008</year><article-title>Inhibition of IL-1 by Anakinra improves vascular and LV function in patients with rheumatoid arthritis.</article-title><source>Circulation</source><volume>117</volume><fpage>2662</fpage><lpage>2669</lpage><pub-id pub-id-type="pmid">18474811</pub-id></citation></ref><ref id="pone.0005073-Abbate1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abbate</surname><given-names>A</given-names></name><name><surname>Salloum</surname><given-names>FN</given-names></name><name><surname>Vecile</surname><given-names>E</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Koke</surname><given-names>NH</given-names></name><etal/></person-group><year>2008</year><article-title>Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.</article-title><source>Circulation</source><volume>117</volume><fpage>2670</fpage><lpage>2683</lpage><pub-id pub-id-type="pmid">18474815</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>Authors SEF and DCC hold limited stock in ILG.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by British Heart Foundation Programme Grant RG 2001/008. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 